ArticleProceedings of the National Academy of Sciences of the United States of America2019
Aspirin-triggered proresolving mediators stimulate resolution in cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease.European journal of clinical pharmacology · 2022Pooled it
- Effects of low-dose acetylsalicylic acid on the inflammatory response to experimental sleep restriction in healthy humans.Brain, behavior, and immunity · 2024Trial
- Trial
- Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial.Journal of periodontology · 2020Trial
- Arachidonic Acid Structure and Synthesis.Reviews of physiology, biochemistry and pharmacology · 2027Review
- Targeted Delivery of Specialized Pro-Resolving Mediators (SPMs) for Improved Treatments of Inflammatory Diseases and Cancer.Pharmaceutics · 2026Review
- Therapeutic repurposing of old drugs to modulate the tumor immune microenvironment and enhance immunotherapy efficacy.Journal of pharmaceutical analysis · 2026Review
- Chronic Inflammation and Cancer Therapy: Molecular Mechanisms and Clinical Advances in Resolution Pharmacology.Biomolecules & therapeutics · 2026Review
- Article
- Unusual and atypical cyclooxygenase reactions.The Journal of biological chemistry · 2026Review
- Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database.BMC gastroenterology · 2025Article
- Aspirin's effect on macrophages beyond its chemopreventive role in inflammation and cancer.Inflammopharmacology · 2025Review
- Reprogramming inflammation: Mechanisms and therapeutic targeting of eicosanoids and pro-resolving mediators.European journal of pharmacology · 2025Review
- Predictive value of neutrophil-to-lymphocyte ratio combined with carcinoembryonic antigen in postoperative adjuvant chemotherapy after gastric cancer surgery.World journal of gastrointestinal oncology · 2025Article
- The association of chronic pain, painkiller use, and potential mediators with liver fat content.Scientific reports · 2025Article
- Lipid-mediated resolution of inflammation and survival in amyotrophic lateral sclerosis.Brain communications · 2025Article
- Aspirin-triggered DHA metabolites inhibit angiogenesis.Frontiers in pharmacology · 2025Article
- EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.Prostaglandins & other lipid mediators · 2024Review
- Systemic administration of Resolvin D1 reduces cancer-induced bone pain in mice: Lack of sex dependency in pain development and analgesia.Cancer medicine · 2024Article
- Enhancing therapeutic efficacy in triple-negative breast cancer and melanoma: synergistic effects of modulated electro-hyperthermia (mEHT) with NSAIDs especially COX-2 inhibition in in vivo models.Molecular oncology · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Inflammation in the tumor microenvironment is a strong promoter of tumor growth. Substantial epidemiologic evidence suggests that aspirin, which suppresses inflammation, reduces the risk of cancer. The mechanism by which aspirin inhibits cancer has remained unclear, and toxicity has limited its clinical use. Aspirin not only blocks the biosynthesis of prostaglandins, but also stimulates the endogenous production of anti-inflammatory and proresolving mediators termed aspirin-triggered specialized proresolving mediators (AT-SPMs), such as aspirin-triggered resolvins (AT-RvDs) and lipoxins (AT-LXs). Using genetic and pharmacologic manipulation of a proresolving receptor, we demonstrate that AT-RvDs mediate the antitumor activity of aspirin. Moreover, treatment of mice with AT-RvDs (e.g., AT-RvD1 and AT-RvD3) or AT-LXA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.